Market Cap 20.46B
Revenue (ttm) 2.98B
Net Income (ttm) -719.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -24.18%
Debt to Equity Ratio 0.01
Volume 2,351,300
Avg Vol 1,168,624
Day's Range N/A - N/A
Shares Out 225.18M
Stochastic %K 35%
Beta 1.51
Analysts Strong Sell
Price Target $138.10

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical tri...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
IndyOne
IndyOne Mar. 12 at 6:14 PM
$BNTX IT WAS A BNTX VS MODERNA CONTEST UNTIL MARCH 10TH. BUY MODERNA (MRNA), CLEAR WINNER. BNTX RUNDOWN: 1. FOUNDERS (CEO AND CMO) LEAVING COMPANY 🕵️‍♂️ * mRNA will be leaking out of BNTX with the best and brightest leaving for the new company * BNTX is giving leaving CEO mRNA technology! Read that again slowly. * Uğur Şahin (CEO that is leaving) remains the full, official CEO of BioNTech during the transition. Conflict of interest - fox in the hen house. 2. BIONTECH REPORTED HORRIBLE RESULTS🪫 * CEO is leaving, what did you expect? * Massive net loss of €1.1B and a cut to 2026 revenue guidance to €2.0–2.3B * In contrast, Moderna had a great quarter and is projecting 10% revenue growth in 2026. 3. BIONTECH'S MRNA? 😭 * If there were great news on clinical trials for BNTX, would the CEO really be leaving right now? * Moderna's V940 just delivered a durable 49% reduction in recurrence or death for melanoma (also lung and bladder cancer applicable).
1 · Reply
Davidendz
Davidendz Mar. 12 at 4:50 PM
Immuno oncology momentum is real. $BNTX expanding oncology. $MRK pushing deeper into bladder with checkpoint combos. Sector trend is clear: vaccines + checkpoint inhibitors = better durability. $BIOV.CSE $BVAXF advancing MVP S with positive multi cancer data, including 24% ORR in ovarian. Platform leverage in a combo driven market.
0 · Reply
taxplanr
taxplanr Mar. 12 at 2:54 PM
Did you know the CIA has known since 1951 that dewormers fight cancer? $BNTX $MRNA $BMY $MRK https://www.msn.com/en-us/health/other/cia-faces-furious-backlash-after-hidden-document-hints-at-possible-cancer-cure/ar-AA1XQBYt
0 · Reply
taxplanr
taxplanr Mar. 12 at 1:56 PM
Will the Fauci pardon be revoked? $BNTX $MRNA $PFE PCR scamdemic https://www.instagram.com/reel/DVqn5ZPl6au/?igsh=aHd0NWtmb2V0eG0y
0 · Reply
taxplanr
taxplanr Mar. 12 at 1:38 PM
Long COVID not as bad as Long COVID Vaccine $BNTX $MRNA $PFE study for next ACIP meeting "PASC and PACVS share symptom overlap but exhibit distinct biomarker patterns, particularly elevated autoantibody levels in PACVS. These findings suggest autoimmune involvement, warranting further investigation for targeted therapies." https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf624/8417802?login=false
0 · Reply
Ventureville
Ventureville Mar. 12 at 12:47 PM
The whole mRNA/immunotherapy arena is firing on all cylinders with $MRNA, $BNTX, and others leveraging AI for next-level vaccines and therapies.
0 · Reply
Pillemann1
Pillemann1 Mar. 12 at 11:44 AM
$BNTX Really did not like that 20% SP hit lately. But Ugur is a scientist by heart. Sure he never ever wanted to run a multi-billion $ company. Victim to his own success. From 2027 onwards he will be back to his roots and Biontech will be properly managed like global corporate with a 11 digit figure in sales. I am absolutely bullish.
0 · Reply
Davidendz
Davidendz Mar. 11 at 8:45 PM
2026 immuno and vax sector is heating up. $MRNA showing durable melanoma control. $BNTX lining up a catalyst heavy year. $PFE staying active on deals. Then $BIOV $BVAXF expanding DPX optionality with the Adiverna mRNA vet collab right after positive Phase 2 bladder data.
0 · Reply
taxplanr
taxplanr Mar. 11 at 8:03 PM
$BNTX setting up nicely for next QR shorting
0 · Reply
BoltTrade
BoltTrade Mar. 11 at 6:07 PM
$SXTP has gone up 55% and still only 2,391 people are watching this stock. Clinical results came in, and all 3 patients were CURED! Let’s talk about 🚀🚀🚀 $VRTX $BNTX $MRNA $CPRX
0 · Reply
Latest News on BNTX
BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript

Mar 10, 2026, 5:40 PM EDT - 2 days ago

BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript


BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls

Mar 10, 2026, 3:39 PM EDT - 2 days ago

BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls


Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:40 AM EDT - 2 days ago

Scientists behind COVID-19 vaccine will depart BioNTech


BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:50 AM EDT - 2 days ago

BioNTech Cofounders to Leave to Form New Company


BioNTech: The Market Is Pricing Low Oncology Success

Feb 25, 2026, 9:46 AM EST - 15 days ago

BioNTech: The Market Is Pricing Low Oncology Success


BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 4 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE


BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 12:46 PM EST - 4 months ago

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript


BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 4 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment


BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 4 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025


Moderna Vs BioNTech: Who's Winning The Post-COVID Race

Oct 18, 2025, 9:30 AM EDT - 5 months ago

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

MRNA


BioNTech SE, InstaDeep Ltd - Special Call

Oct 1, 2025, 6:52 PM EDT - 5 months ago

BioNTech SE, InstaDeep Ltd - Special Call


mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 7 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY DHR GRAL ILMN IONS MRNA RGEN


IndyOne
IndyOne Mar. 12 at 6:14 PM
$BNTX IT WAS A BNTX VS MODERNA CONTEST UNTIL MARCH 10TH. BUY MODERNA (MRNA), CLEAR WINNER. BNTX RUNDOWN: 1. FOUNDERS (CEO AND CMO) LEAVING COMPANY 🕵️‍♂️ * mRNA will be leaking out of BNTX with the best and brightest leaving for the new company * BNTX is giving leaving CEO mRNA technology! Read that again slowly. * Uğur Şahin (CEO that is leaving) remains the full, official CEO of BioNTech during the transition. Conflict of interest - fox in the hen house. 2. BIONTECH REPORTED HORRIBLE RESULTS🪫 * CEO is leaving, what did you expect? * Massive net loss of €1.1B and a cut to 2026 revenue guidance to €2.0–2.3B * In contrast, Moderna had a great quarter and is projecting 10% revenue growth in 2026. 3. BIONTECH'S MRNA? 😭 * If there were great news on clinical trials for BNTX, would the CEO really be leaving right now? * Moderna's V940 just delivered a durable 49% reduction in recurrence or death for melanoma (also lung and bladder cancer applicable).
1 · Reply
Davidendz
Davidendz Mar. 12 at 4:50 PM
Immuno oncology momentum is real. $BNTX expanding oncology. $MRK pushing deeper into bladder with checkpoint combos. Sector trend is clear: vaccines + checkpoint inhibitors = better durability. $BIOV.CSE $BVAXF advancing MVP S with positive multi cancer data, including 24% ORR in ovarian. Platform leverage in a combo driven market.
0 · Reply
taxplanr
taxplanr Mar. 12 at 2:54 PM
Did you know the CIA has known since 1951 that dewormers fight cancer? $BNTX $MRNA $BMY $MRK https://www.msn.com/en-us/health/other/cia-faces-furious-backlash-after-hidden-document-hints-at-possible-cancer-cure/ar-AA1XQBYt
0 · Reply
taxplanr
taxplanr Mar. 12 at 1:56 PM
Will the Fauci pardon be revoked? $BNTX $MRNA $PFE PCR scamdemic https://www.instagram.com/reel/DVqn5ZPl6au/?igsh=aHd0NWtmb2V0eG0y
0 · Reply
taxplanr
taxplanr Mar. 12 at 1:38 PM
Long COVID not as bad as Long COVID Vaccine $BNTX $MRNA $PFE study for next ACIP meeting "PASC and PACVS share symptom overlap but exhibit distinct biomarker patterns, particularly elevated autoantibody levels in PACVS. These findings suggest autoimmune involvement, warranting further investigation for targeted therapies." https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf624/8417802?login=false
0 · Reply
Ventureville
Ventureville Mar. 12 at 12:47 PM
The whole mRNA/immunotherapy arena is firing on all cylinders with $MRNA, $BNTX, and others leveraging AI for next-level vaccines and therapies.
0 · Reply
Pillemann1
Pillemann1 Mar. 12 at 11:44 AM
$BNTX Really did not like that 20% SP hit lately. But Ugur is a scientist by heart. Sure he never ever wanted to run a multi-billion $ company. Victim to his own success. From 2027 onwards he will be back to his roots and Biontech will be properly managed like global corporate with a 11 digit figure in sales. I am absolutely bullish.
0 · Reply
Davidendz
Davidendz Mar. 11 at 8:45 PM
2026 immuno and vax sector is heating up. $MRNA showing durable melanoma control. $BNTX lining up a catalyst heavy year. $PFE staying active on deals. Then $BIOV $BVAXF expanding DPX optionality with the Adiverna mRNA vet collab right after positive Phase 2 bladder data.
0 · Reply
taxplanr
taxplanr Mar. 11 at 8:03 PM
$BNTX setting up nicely for next QR shorting
0 · Reply
BoltTrade
BoltTrade Mar. 11 at 6:07 PM
$SXTP has gone up 55% and still only 2,391 people are watching this stock. Clinical results came in, and all 3 patients were CURED! Let’s talk about 🚀🚀🚀 $VRTX $BNTX $MRNA $CPRX
0 · Reply
BPler
BPler Mar. 11 at 4:59 PM
$CRVO 3 days in a row borrow fees under 7%. Doesn't look like big short bets before earnings next week. Btw: If you look at the founders from $BNTX , you can see how non-dillutive funding can work. E.g. sharing future revenue or exclusive licensing rights. If they pull that off, this goes straight above 30+. Would explain the investor matching activities, which you don't need for direct dilution
1 · Reply
topstockalerts
topstockalerts Mar. 11 at 4:34 PM
$BNTX Vaccine developer that still commands attention when infectious disease headlines surface. Pipeline progress or new partnership announcements usually dictate the next move.
0 · Reply
erevnon
erevnon Mar. 11 at 4:04 PM
Citigroup maintains BioNTech $BNTX at Buy and lowers the price target from $145 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
wheresdannynow
wheresdannynow Mar. 11 at 3:57 PM
Immuno-oncology + mRNA cancer vaccine race still heating up in 2026. Market tracking toward $170B+ by early 2030s. Leaders pushing trials and data: $BNTX $MRNA $IBRX. Smaller platforms still advancing pipelines like $IMVIF $BIOV.CSE $BVAXF Major catalysts ahead across cancer vax, CAR-T, and checkpoint combos.
0 · Reply
taxplanr
taxplanr Mar. 11 at 3:46 PM
$BNTX $MRNA $PFE Do you remember when ... https://www.instagram.com/reel/DVjfEuxj2Uy/?igsh=a3F5anphaTMxYm41
0 · Reply
htw7448
htw7448 Mar. 11 at 3:20 PM
$BNTX luv all this instant cash. Bought heavily calls yesterday 😂
0 · Reply
erevnon
erevnon Mar. 11 at 3:19 PM
TD Cowen maintains BioNTech $BNTX at Hold and lowers the price target from $116 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
erevnon
erevnon Mar. 11 at 3:08 PM
BMO Capital maintains BioNTech $BNTX at Outperform and lowers the price target from $143 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
taxplanr
taxplanr Mar. 11 at 2:39 PM
Here is what real Cancer cure results and manufacturing look like $BNTX $MRNA $BMY $MRK
0 · Reply
Bmdubb
Bmdubb Mar. 11 at 2:28 PM
$BNTX ✌🏾
0 · Reply
Trackdips
Trackdips Mar. 11 at 2:23 PM
Why the buy the dip tracker can work with swing trading. $BNTX was down 23% at its lowest , it recovered 5% yesterday and another 10% today. The stock had the highest bounce probability
0 · Reply
taxplanr
taxplanr Mar. 11 at 2:19 PM
$BNTX losing a Billion or more for the next 3 years
1 · Reply